IMRN:NASDAQ
Immuron Ltd - ADR
$1.11
arrow_upward
+1.83%(+0.020) 1D
Oct 8, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for IMRN...
Open
$1.10
High
$1.17
Low
$1.09
Mkt. cap
10.33M
Avg. vol.
4.37M
Volume
0.00
52-wk high
$2.38
52-wk low
$0.68
EPS
-$0.35
Beta
1.09
Shares outstanding
8.07M
No. of employees
8
Open
$1.10
High
$1.17
Low
$1.09
Mkt. cap
10.33M
Avg. vol.
4.37M
Volume
0.00
52-wk high
$2.38
52-wk low
$0.68
EPS
-$0.35
Beta
1.09
Shares outstanding
8.07M
No. of employees
8
News stories
From web sources and news partners
pharmaphorum
·
32 minutes ago
Iambic prices its IPO, seeking to raise up to $160m
The Tech Buzz
·
55 minutes ago
Nasdaq CEO: Tokenization Could Free Tens of Billions in Capital
Seeking Alpha
·
25 minutes ago
S&P 500 Sector Outlook: Favor XLC And XLK, Underweight XLP With Uneven Earnings Leadership
Profile
Immuron is a biotechnology company based in Melbourne, Australia. In 2008, the company changed its name to Immuron Limited, having previously operated as Anadis Limited.
Immuron is focused on antigen-primed and dairy-derived health products. Its proprietary technologies allow for rapid development of polyclonal antibody and other proteins-based solutions for a range of diseases. The company specialises in nutraceutical, pharmaceutical and therapeutic technology products for conditions such as oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea and Anthrax containment.
In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market. Wikipedia
About Immuron Ltd - ADR
CEO-
Employees8
Founded1994
HeadquartersBlackburn North, Victoria, Australia
SectorBiotechnology
Websiteimmuron.com.au